Company: PETVW
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001493152-25-006783
Chunk: 40

Company: PetVivo Holdings, Inc.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---

    $1.65 

    $2.01-$4.00 
     80,000  
     2.34  
     0.25  
     80,00  
     2.34 

    $4.01-$5.63 
     3,043,556  
     5.63  
     1.58  
     3,043,556  
     5.63 

    Total 
     12,903,128  
    $2.42  
     2.16  
     12,903,128  
    $2.34 

Stock-based
compensation expense included in the Consolidated Statements of Operations for warrants was $115,853 and $58,685 for the three months
ended December 31, 2024, and 2023, respectively and $267,626 and $204,855 for the nine months ended December 31, 2024, and 2023, respectively.
At December 31, 2024, there was $1,525,000 of future unrecognized warrant expense.

For
the nine months ended December 31, 2024 and 2023, the total stock-based compensation on all instruments was $1,017,242 and $1,537,437,
respectively.

NOTE
13 – SUBSEQUENT EVENTS

From
January 1, 2025, through the date of this quarterly report 10Q filing, the Company sold 950,000 restricted common shares to nine accredited
investors who purchased the shares for $617,500 at $0.65 per share.

27

ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL

PetVivo
Holdings, Inc. (the “Company,” “PetVivo,” “we” or “us) is an emerging biomedical device company
focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The Company
has a pipeline of products for the treatment of animals. A portfolio of nineteen patents protects the Company’s biomaterials, products,
production processes, and methods of use. The Company began commercialization of its lead product Spryng™ with OsteoCushion™
Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflict